Martina Garau : Citation Profile


Are you Martina Garau?

Office of Health Economics

3

H index

1

i10 index

30

Citations

RESEARCH PRODUCTION:

1

Articles

21

Papers

1

Books

RESEARCH ACTIVITY:

   12 years (2006 - 2018). See details.
   Cites by year: 2
   Journals where Martina Garau has often published
   Relations with other researchers
   Recent citing documents: 9.    Total self citations: 6 (16.67 %)

MORE DETAILS IN:
ABOUT THIS REPORT:

   Permalink: http://citec.repec.org/pga966
   Updated: 2019-12-07    RAS profile: 2018-12-18    
   Missing citations? Add them    Incorrect content? Let us know

Relations with other researchers


Works with:

Towse, Adrian (4)

Devlin, Nancy (2)

Shah, Koonal (2)

Neri, Margherita (2)

Hampson, Grace (2)

Authors registered in RePEc who have co-authored more than one work in the last five years with Martina Garau.

Is cited by:

Towse, Adrian (4)

Shah, Koonal (3)

Culyer, Anthony (1)

Rotolo, Daniele (1)

Sanchez Martinez, Fernando Ignacio (1)

Tsuchiya, Aki (1)

Berdud, Mikel (1)

pinto-prades, jose-luis (1)

Brazier, John (1)

Cites to:

Towse, Adrian (8)

Devlin, Nancy (7)

Danzon, Patricia (4)

Rice, Nigel (3)

Shah, Koonal (3)

Docteur, Elizabeth (3)

Parkin, David (3)

Andreoni, James (3)

Brouwer, Werner (2)

O'Neill, Phill (2)

Aghion, Philippe (2)

Main data


Where Martina Garau has published?


Working Papers Series with more than one paper published# docs
Consulting Reports / Office of Health Economics10
Research Papers / Office of Health Economics7
Briefings / Office of Health Economics3

Recent works citing Martina Garau (2018 and 2017)


YearTitle of citing document
2018Funding breakthrough therapies: A systematic review and recommendation. (2018). Hanna, E ; Auquier, P ; Badora, K ; Dabbous, O ; Borissov, B ; Dussart, C ; Toumi, M. In: Health Policy. RePEc:eee:hepoli:v:122:y:2018:i:3:p:217-229.

Full description at Econpapers || Download paper

2019Using a stated preference discrete choice experiment to assess societal value from the perspective of decision-makers in Europe. Does it work for rare diseases?. (2019). Trapero-Bertran, M ; Aranda-Reneo, I ; Ramos-Goi, J M ; Lopez-Bastida, J ; Martin, Rodriguez B ; Kanavos, P. In: Health Policy. RePEc:eee:hepoli:v:123:y:2019:i:2:p:152-158.

Full description at Econpapers || Download paper

2019Competition between on-patent medicines in Europe. (2019). Wilsdon, Tim ; Roediger, Alexander ; Azais, Boris ; Pendleton, Kathy ; Haderi, Artes. In: Health Policy. RePEc:eee:hepoli:v:123:y:2019:i:7:p:652-660.

Full description at Econpapers || Download paper

2018The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century. (2018). Bagley, Nicholas ; Stern, Ariel Dora ; Garthwaite, Craig ; Chandra, Amitabh. In: NBER Chapters. RePEc:nbr:nberch:14097.

Full description at Econpapers || Download paper

2018Establishing a Reasonable Price for an Orphan Drug. (2018). Berdud, Mikel ; Towse, A ; Drummon, M F. In: Research Papers. RePEc:ohe:respap:002036.

Full description at Econpapers || Download paper

2017Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval. (2017). Chambers, James D ; Neumann, Peter J ; Kamal-Bahl, Sachin J ; Subedi, Prasun ; Salem, Mark ; Wilkinson, Colby L ; Thorat, Teja . In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:15:y:2017:i:2:d:10.1007_s40258-016-0291-9.

Full description at Econpapers || Download paper

2017Amplifying Each Patient’s Voice: A Systematic Review of Multi-criteria Decision Analyses Involving Patients. (2017). Marsh, Kevin ; Zaiser, Erica ; Hamed, Alaa ; Caro, Jaime J. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:15:y:2017:i:2:d:10.1007_s40258-016-0299-1.

Full description at Econpapers || Download paper

2018Does MCDA Trump CEA?. (2018). Culyer, Anthony ; Puig-Junoy, Jaume ; Campillo-Artero, Carlos. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:16:y:2018:i:2:d:10.1007_s40258-018-0373-y.

Full description at Econpapers || Download paper

2018New Medicines in Wales: The All Wales Medicines Strategy Group (AWMSG) Appraisal Process and Outcomes. (2018). Varnava, Alice ; Routledge, Philip A ; Hughes, Dyfrig A ; Samuels, Karen ; Bracchi, Robert. In: PharmacoEconomics. RePEc:spr:pharme:v:36:y:2018:i:5:d:10.1007_s40273-018-0632-7.

Full description at Econpapers || Download paper

Works by Martina Garau:


YearTitleTypeCited
2009Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries In: Briefings.
[Full Text][Citation analysis]
paper5
2007Estimating Pharmaceutical Companies Value to the Nation: Case Study of the British Pharma Group In: Briefings.
[Full Text][Citation analysis]
paper0
2018Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward In: Briefings.
[Full Text][Citation analysis]
paper0
2011Exploring the Interdependency between Public and Charitable Medical Research In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2010Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2009Assessment and Appraisal of Oncology Medicines: NICEs Approach and International HTA Experience In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2006Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2014Obstructive Sleep Apnoea: Health Economics Report In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2016Improving Efficiency and Resource Allocation in Future Cancer Care In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2017Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2017Policy Options for Formulary Development in Middle-income Countries In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2017Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries In: Consulting Reports.
[Full Text][Citation analysis]
paper1
2018Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence In: Consulting Reports.
[Full Text][Citation analysis]
paper0
2007European Medicines Pricing and Reimbursement: Now and the Future In: Monographs.
[Full Text][Citation analysis]
book0
2011Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? In: Occasional Papers.
[Full Text][Citation analysis]
paper1
2013Exploring the link between health and wealth in decision making In: Research Papers.
[Full Text][Citation analysis]
paper0
2013Multi-Criteria Decision Analysis to Value Orphan Medicines In: Research Papers.
[Full Text][Citation analysis]
paper10
2012Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? In: Research Papers.
[Full Text][Citation analysis]
paper3
2010Using QALYs in Cancer: Review of the Methodological Limitations In: Research Papers.
[Full Text][Citation analysis]
paper8
2014Exploring the Interdependencies of Research Funders in the UK In: Research Papers.
[Full Text][Citation analysis]
paper1
2016Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: Research Papers.
[Full Text][Citation analysis]
paper0
2018Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).(2018) In: PharmacoEconomics - Open.
[Full Text][Citation analysis]
This paper has another version. Agregated cites: 0
article
2018R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C In: Research Papers.
[Full Text][Citation analysis]
paper1

CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated December, 2nd 2019. Contact: CitEc Team